Literature DB >> 2503687

Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats.

D W Wilson1, H J Segall, L C Pan, S K Dunston.   

Abstract

The progression of changes in the bronchus-associated and intraacinar pulmonary arteries of rats treated with a single dose of monocrotaline (60 mg/kg) was evaluated by quantitative light and electron microscopy. The relative volume of vessel wall components was normalized to the surface area of the adventitial sheath. An increased relative volume of media was evident in intraacinar pulmonary arteries by 4 hr post-treatment. This increase may represent vascular smooth muscle contraction. Significant increases in adventitial mononuclear inflammatory cells were evident by 8-16 hr post-treatment in intraacinar pulmonary arteries and veins but not until 14 days post-treatment in major, bronchus-associated pulmonary arteries. Inflammatory cell influxes were associated with increased relative volume of adventitia, largely due to increased extracellular space. By 22 days posttreatment, there was right ventricular hypertrophy and a marked mononuclear vasculitis in major and intraacinar pulmonary arteries as well as intraacinar veins (confirmed as such by vascular perfusion of carbon/gelatin). There was increased relative medial volume in both major and intraacinar pulmonary arteries associated with increased extracellular matrix composed largely of collagen. Intraacinar veins developed intimal plaques of smooth muscle in a collagenous matrix. We conclude that (1) adventitial inflammation precedes morphologic evidence of medial changes in monocrotaline-induced pulmonary hypertension, (2) involvement of intraacinar arteries precedes that of major bronchus associated arteries, and (3) both pulmonary arteries and veins are involved in monocrotaline-induced pulmonary vascular disease in the rat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503687     DOI: 10.1016/0026-2862(89)90017-4

Source DB:  PubMed          Journal:  Microvasc Res        ISSN: 0026-2862            Impact factor:   3.514


  27 in total

1.  Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Authors:  Michael L Paffett; Selita N Lucas; Matthew J Campen
Journal:  Vascul Pharmacol       Date:  2011-11-25       Impact factor: 5.773

2.  Changes in type II cell populations in monocrotaline pneumotoxicity.

Authors:  D W Wilson; H J Segall
Journal:  Am J Pathol       Date:  1990-06       Impact factor: 4.307

3.  Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.

Authors:  K Okada; Y Tanaka; M Bernstein; W Zhang; G A Patterson; M D Botney
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 5.  Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension.

Authors:  Brandon L Carman; Dan N Predescu; Roberto Machado; Sanda A Predescu
Journal:  Am J Pathol       Date:  2019-03-26       Impact factor: 4.307

Review 6.  Right Ventricular-Pulmonary Vascular Interactions.

Authors:  Diana M Tabima; Jennifer L Philip; Naomi C Chesler
Journal:  Physiology (Bethesda)       Date:  2017-09

7.  Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage.

Authors:  Michael J Cuttica; Thomas Langenickel; Audrey Noguchi; Roberto F Machado; Mark T Gladwin; Manfred Boehm
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-02       Impact factor: 6.914

8.  Myocardial oxidative stress changes during compensated right heart failure in rats.

Authors:  J Pichardo; V Palace; F Farahmand; P K Singal
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

9.  Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension.

Authors:  Gopinath Sutendra; Peter Dromparis; Sébastien Bonnet; Alois Haromy; Michael S McMurtry; R Chris Bleackley; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2011-08-02       Impact factor: 4.599

10.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.